KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Other Accumulated Expenses (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Other Accumulated Expenses for 5 consecutive years, with $1.5 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other Accumulated Expenses fell 35.89% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Dec 2024, down 35.89%, and an annual FY2024 reading of $1.5 million, down 35.89% over the prior year.
  • Other Accumulated Expenses was $1.5 million for Q4 2024 at Aurinia Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $6.5 million in Q3 2021 and bottomed at $502000.0 in Q1 2022.
  • Average Other Accumulated Expenses over 4 years is $2.2 million, with a median of $2.0 million recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses tumbled 88.79% in 2022, then skyrocketed 294.22% in 2023.
  • Year by year, Other Accumulated Expenses stood at $4.4 million in 2021, then crashed by 54.31% to $2.0 million in 2022, then increased by 17.46% to $2.4 million in 2023, then tumbled by 35.89% to $1.5 million in 2024.
  • Business Quant data shows Other Accumulated Expenses for AUPH at $1.5 million in Q4 2024, $1.6 million in Q3 2024, and $1.2 million in Q1 2024.